: Merck swings to loss as it books charge on $10.8 billion acquisition of Prometheus Biosciences

Merck’s earnings were also hit by lower sales of its COVID antiviral Lagevrio.

Previous post Realtor.com: Singer and beauty boss Rihanna unloads one of her Beverly Hills homes for $10.3 million
Next post In One Chart: China data is ‘grim reading’ for commodities demand, economist says